Literature DB >> 21711136

Failure after laparoscopic pyeloplasty: prevention and management.

Hung-Jui Tan1, Zaojun Ye, William W Roberts, J Stuart Wolf.   

Abstract

BACKGROUND AND
PURPOSE: Because of the high success of laparoscopic pyeloplasty (LP) for ureteropelvic junction obstruction, strategies for managing failures are less well described. We report our experience with persistent or recurrent obstruction after LP. PATIENTS AND METHODS: We reviewed 128 patients who were treated with LP at our institution from 1996 through 2008. Success was defined as objective resolution of obstruction by renal scintigraphy, Whitaker testing, or direct visualization. We extracted data by chart review regarding patient demographics, medical history, operative technique, and salvage treatments. We then assessed for association between patient characteristics and treatment failure.
RESULTS: Overall, 102 patients had sufficient follow-up, of which 84 (82%) were successes. Of 18 failures, median time to failure was 2.5 months (0.5-88 mos). Of 10 failures managed endoscopically, 7 were salvaged. One of two patients treated conservatively ultimately had resolution while six patients needed simple nephrectomy. Overall, 8 (44%) were salvageable with median follow-up of 19 months (4-58 mos). Patients with failure were more likely to have diabetes mellitus, longer length of stay, higher American Society of Anesthesiologists (ASA) score, a stent placed at the time of pyeloplasty, or ureteral stent malfunction (P<0.05). Patients with failure despite salvage were more likely to have stent malfunction or body mass index >30 kg/m(2) (P<0.05). Adjusting for the above factors, stent placement at time of surgery and ASA score >2 were associated with failure (P<0.05) while periureteral fibrosis trended toward a significant association (P=0.061).
CONCLUSION: Nearly half of failures after LP are salvageable, many with endoscopic management.

Entities:  

Mesh:

Year:  2011        PMID: 21711136     DOI: 10.1089/end.2010.0647

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  8 in total

1.  Matched comparison of primary versus salvage laparoscopic pyeloplasty.

Authors:  Sapan N Ambani; David Y Yang; J Stuart Wolf
Journal:  World J Urol       Date:  2016-10-08       Impact factor: 4.226

2.  The Comparative Effectiveness of Treatments for Ureteropelvic Junction Obstruction.

Authors:  Bruce L Jacobs; Julie C Lai; Rachana Seelam; Janet M Hanley; J Stuart Wolf; Brent K Hollenbeck; John M Hollingsworth; Andrew W Dick; Claude M Setodji; Christopher S Saigal
Journal:  Urology       Date:  2017-09-21       Impact factor: 2.649

3.  Long-term follow-up results of laparoscopic pyeloplasty.

Authors:  Ill Young Seo; Tae Hoon Oh; Jae Whan Lee
Journal:  Korean J Urol       Date:  2014-10-10

4.  Trends in the treatment of adults with ureteropelvic junction obstruction.

Authors:  Bruce L Jacobs; Samuel R Kaufman; Hal Morgenstern; Brent K Hollenbeck; J Stuart Wolf; John M Hollingsworth
Journal:  J Endourol       Date:  2012-11-07       Impact factor: 2.942

5.  Complex Re-do robotic pyeloplasty using cryopreserved placental tissue: an adjunct for success.

Authors:  Adam Cole; Matthew Lee; Zachary Koloff; Khurshid R Ghani
Journal:  Int Braz J Urol       Date:  2021 Jan-Feb       Impact factor: 1.541

6.  Redo laparoscopic pyeloplasty for recurrent ureteropelvic junction obstruction: Propensity score matched analyses of a high-volume center.

Authors:  Jiayi Li; Yang Yang; Zonghan Li; Songqiao Fan; Xinyu Wang; Zhenzhen Yang; Pei Liu; Hongcheng Song; Weiping Zhang
Journal:  Front Pediatr       Date:  2022-09-08       Impact factor: 3.569

Review 7.  Management of ureteropelvic junction obstruction in adults.

Authors:  Fahd Khan; Kamran Ahmed; Nikiesha Lee; Ben Challacombe; Mohammed S Khan; Prokar Dasgupta
Journal:  Nat Rev Urol       Date:  2014-10-07       Impact factor: 14.432

8.  Management of secondary pelviureteric junction obstruction.

Authors:  Alistair Rogers; Tahseen Hasan
Journal:  Indian J Urol       Date:  2013-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.